Page 58 - NobleCon19revC2_Neat

Health Care
Date November 21, 2023 Health Care
52wk High $1.71
52wk Low $0.60 Citius Pharmaceuticals, Inc. CTXR $0.78
11 Commerce Drive
Cranford, NJ 07016

(USD - in millions) www.citiuspharma.com
Market Cap 121.9
Enterprise 89.7
Basic Shares Out. 158.86 COMPANY OVERVIEW
Float 146.53
Institutional Holdings 15.65% Detailed Analysis:Channelchek.com
Short Interest 16.89
Avg. 90-Day Volume 0.64 Citius Pharmaceuticals Inc is a specialty pharmaceutical company. The
company is engaged in the development and commercialization of anti-
infective products, adjunctive cancer care, and unique prescription
products. Citius is currently advancing two proprietary product
EPS Data candidates, Mino-Lok product and a Hydrocortisone-Lidocaine
formulation. Mino-Lok product is an antibiotic lock solution used to treat
2021 2022 2023 patients with catheter-related bloodstream infections. The company’s
CQ1 (0.04) (0.05) (0.07) Hydrocortisone-Lidocaine provides anti-inflammatory and anesthetic
CQ2 (0.05) (0.06) (0.06) relief to patients suffering from Grade I and II hemorrhoids. It is
primarily operating within the critical care and cancer care market
CQ3 (0.03) (0.05) (0.06) segments.
CQ4 (0.06) N/A N/A
CY (0.18) (0.23) (0.18) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.62
ROE (ttm) -29.32
Debt-to-Total Cap. (mrq) 0.54
Fiscal Year End 30-Sep
11 Commerce Cranford NJ 07016

Key Executives
CEO: Mazur, Leonard
CFO: Bartushak, Jaime
COO: Talarico, Gary
IR: Allen, Ilanit
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures